Discover the new migraine medications, such as monoclonal antibodies and gepants, that are changing migraine treatment for ...

Individuals living near golf courses, as well as those who reside in water service areas that include golf courses, are at ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

In an effort to offset declining COVID-19 product sales, Pfizer embarked on an aggressive acquisition strategy, purchasing Seagen, Global Blood Therapeutics, and Biohaven. While the Seagen ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

If it wins approval, troriluzole would represent Biohaven’s first greenlit product since it spun out from its migraine business following a $11.6bn acquisition from Pfizer back in 2022.

Pfizer has increased its dividend for 16 straight ... including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical) and cancer drug Padcev (picked up ...